Limaprost is an analog of PGE1 with structural modifications intended to give it a prolonged half-life and greater potency. Limaprost is orally active in both rats and guinea pigs at doses of 100 µg/kg as an inhibitor of ADP and collagen induced platelet aggregation. Limaprost is 10-1,000 times more potent than PGE1 as an inhibitor of platelet adhesiveness measured in vitro. Intra coronary injection (100 ng/kg) or intravenous injection (3 µg/kg) in anesthetized dogs causes vasodilation and increased coronary blood flow by 60-80%. Significant hypotensive effects were seen at 100 and 300 µg/kg orally in rats.